B Group, Inc.

In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 14, 2025), B Group, Inc. reported 15 stock positions worth $115.8 million. Its top holding was Adma Biologics (ADMA) at 36.4% of the portfolio, followed by Insmed (INSM, 13.5%) and Zai Lab Ltd.-ADR (ZLAB, 12.1%). Compared with Q1 2025, it sold out of 2, added to 8 and reduced 3. The biggest buy was Taysha Gene Therapies (TSHA, shares +43%) and the biggest sale Insmed (INSM, shares −41%).

Most Recent 13F
Q2 2026
Location
DALLAS, TX
CIK
0002043476
Portfolio Value
$115.8M (Q2 2025)
SEC Filing
0001420506-25-002005 ↗ filed Aug 14, 2025

Holdings Value

0$50.0M$100.0M$150.0M$200.0M Q4 2024: $163.6M Q4 2024 Q1 2025: $115.1M Q1 2025 Q2 2025: $115.8M $115.8M Q2 2025 Q3 2025: $100.1M Q3 2025 Q4 2025: $134.9M Q4 2025 Q1 2026: $134.9M Q1 2026 Q2 2026: $176.2M Q2 2026

Holdings 15 stocks · $115.8M
ADMA Adma Biologics Inc. 36.45% 2,317,542 $42.2M No change
INSM Insmed Inc. 13.47% 155,000 $15.6M Reduce -41.0%
ZLAB Zai Lab Ltd.-ADR 12.08% 400,000 $14.0M No change
AKRO Akero Therapeutics Inc. 10.71% 232,446 $12.4M Reduce -4.2%
CLLS Cellectis - ADR 4.29% 3,256,501 $5.0M No change
TSHA Taysha Gene Therapies Inc. 3.59% 1,800,556 $4.2M Add +43.4%
RARE Ultragenyx Pharmaceutical Inc. 3.45% 110,000 $4.0M Add +131.6%
SGHT Sight Sciences Inc. 3.32% 930,000 $3.8M Add +11.6%
AURA Aura Biosciences Inc. 3.10% 572,576 $3.6M Add +21.2%
ASMB Assembly Biosciences Inc. 2.96% 189,350 $3.4M Reduce -5.3%
IOVA Iovance Biotherapeutics Inc. 2.23% 1,500,000 $2.6M No change
APGE Apogee Therapeutics Inc. 1.31% 35,000 $1.5M Add +16.7%
PRAX Praxis Precision Medicines I 1.27% 35,000 $1.5M Add +84.2%
SYRE Spyre Therapeutics Inc. 1.03% 80,000 $1.2M Add +14.3%
ORKA Oruka Therapeutics Inc. 0.73% 75,000 $841K Add +28.8%

Options reported separately and not counted above: ELI LILLY & CO puts ($11.7M), ULTRAGENYX PHARMACEUTICAL IN calls ($2.5M).

Portfolio Sells Q1 2025 → Q2 2025
INSM Insmed Inc. Reduce -41.0% 13.47% −3.93
BNTX Biontech SE-ADR Sold out 0.00% −1.19
ETNB 89BIO Inc. Sold out 0.00% −0.60
ASMB Assembly Biosciences Inc. Reduce -5.3% 2.96% +1.30
AKRO Akero Therapeutics Inc. Reduce -4.2% 10.71% +2.18

Portfolio Buys Q1 2025 → Q2 2025
TSHA Taysha Gene Therapies Inc. Add +43.4% 3.59% +2.08
RARE Ultragenyx Pharmaceutical Inc. Add +131.6% 3.45% +1.96
SGHT Sight Sciences Inc. Add +11.6% 3.32% +1.58
AURA Aura Biosciences Inc. Add +21.2% 3.10% +0.69
PRAX Praxis Precision Medicines I Add +84.2% 1.27% +0.65
APGE Apogee Therapeutics Inc. Add +16.7% 1.31% +0.34
ORKA Oruka Therapeutics Inc. Add +28.8% 0.73% +0.21
SYRE Spyre Therapeutics Inc. Add +14.3% 1.03% +0.05

Options Activity Q1 2025 → Q2 2025
ELI LILLY & CO put New 15,000 $11.7M
ULTRAGENYX PHARMACEUTICAL IN call Add +79.8% 67,600 $2.5M
CORVUS PHARMACEUTICALS INC put Sold out 90,000 $286Kbefore exit

Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 18$176.2MADMA, PALI, NRXP, FTH, TSHA
Q1 2026 20$134.9MADMA, PALI, PRAX, CLLS, ZLAB
Q4 2025 15$134.9MADMA, CLLS, PALI, TSHA, PRAX
Q3 2025 16$100.1MADMA, ZLAB, AKRO, CLLS, TSHA
Q2 2025 15$115.8MADMA, INSM, ZLAB, AKRO, CLLS
Q1 2025 17$115.1MADMA, INSM, ZLAB, AKRO, IOVA
Q4 2024 18$163.6MINVESCO QQQ TR, ADMA, INSM, ZLAB, IOVA